Breaking News, Collaborations & Alliances

Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics

Zynlonta is an antibody drug conjugate approved for cancer treatment.

Author Image

By: Charlie Sternberg

Associate Editor

Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing development and manufacturing services to biotechnology and pharmaceutical companies, will serve as the commercial manufacturer for the humanized monoclonal antibody portion of Zynlonta (loncastuximab tesirine-lpyl), a recently approved cancer treatment developed by ADC Therapeutics SA.   Avid has provided clinical manufacturing services to ADC The...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters